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Description

Metastasis-induced acute pancreatitis (MIAP) is a condition that occurs when patients
develop acute pancreatitis secondary to metastatic malignancy. Most pancreatic cancers are
adenocarcinomas that are primary malignancies. On the other hand, metastatic pancreatic
lesions are rare, especially from primary pulmonary malignancies. Acute pancreatitis caused
by metastatic carcinoma of the pancreas is a very rare presentation. Herein, we present
the case of a 63-year-old male with history of small-cell lung carcinoma presenting to the
hospital due to recurrent episodes of acute pancreatitis who was found to have metastatic
pancreatic carcinoma. The patient was treated conservatively for his recurrent acute pancreatitis, had a stent placed in the common bile duct to relieve obstruction, and planned for
outpatient palliative chemotherapy.
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Introduction

Metastasis-induced acute pancreatitis (MIAP)
is a rare presentation in patients with primary
pulmonary malignancies. Small-cell lung carcinoma (SCLC) is known to metastasize rapidly,
commonly to the contralateral lung, brain, liver,
adrenal glands, and bone.1 Although unusual,
SCLC has been previously observed metastasizing to the pancreas.2 Patients with histories
of SCLC presenting to the hospital with acute
pancreatitis should be further investigated for
the presence of new pancreatic lesions. The
presence of metastatic SCLC to the pancreas
often indicates advanced staging of the cancer
and poorer prognosis for the patient.3 Treatment should be tailored to the patient’s informed decision once properly educated on the
disease and its prognosis.

Case Presentation

A 63-year-old male with a past medical history of recently diagnosed SCLC, who had been

treated with cisplatin, etoposide chemotherapy, and radiation therapy, presented to our
emergency department with a 3-day history
of intermittent non-radiating epigastric abdominal pain along with nausea and multiple
episodes of non-bloody vomiting. The patient
reported no alcohol consumption or history of cholelithiasis. On presentation, his vital
signs were within normal limits. The physical
examination was unremarkable. Initial laboratory studies including complete blood count,
chemistry panel, and hepatic function panel
were notable only for lipase of 4509 units/L.
Alanine transaminase (ALT), aspartate transaminase (AST), and alkaline phosphatase
(ALP) were within normal limits. Computed
tomography (CT) of the abdomen and pelvis with IV contrast (Figure 1) demonstrated
moderate peripancreatic edema characteristic
of acute pancreatitis with no pancreatic mass
or pseudocyst. The patient remained in the
hospital for a total of 3 days, where he received
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Figure 1. A CT of the abdomen and pelvis with IV contrast showed a moderate degree of peripancreatic edema surrounding the body of the pancreas (yellow circle).
IV fluids and pain medications, and was discharged after symptoms resolved.
Ten days later, the patient returned to the
emergency department with complaints of
persistent epigastric pain. Vital signs were
within normal limits. Repeat laboratory studies including complete blood count, chemistry
panel, and hepatic function panel were notable
only for lipase 2782 units/L. Repeat AST, ALT,
and ALP were within normal limits. Magnetic
resonance imaging (MRI) without contrast and
with magnetic resonance cholangiopancreatography (MRCP) of the abdomen (Figure 2)
revealed a heterogenous pancreas with multiple focal pancreatic and peripancreatic lesions.
Endoscopic ultrasound demonstrated multiple
hypoechoic lesions in the pancreatic body, tail,
and peripancreatic area. A fine needle biopsy
was performed on the pancreatic body lesion,
A

which was positive for metastatic SCLC. The
biopsy was also positive for CAM5.2, TTF1, synaptophysin, and chromogranin tumor
markers. The oncology team was consulted and
the decision was made to start the patient on
topotecan chemotherapy for the new metastatic pancreatic mass as an outpatient. The
patient remained in the hospital for a total of 12
days and was discharged home after symptoms
resolved.
Eight days following the second discharge, the
patient returned to the emergency department
with complaints of recurrent abdominal pain as
well as new onset of jaundice. Vital signs were
within normal limits. Repeat laboratory studies
including complete blood count, chemistry panel, and hepatic function panel were notable for
lipase 1443 units/L, AST of 94 units/L, ALT of
182 units/L, ALP of 1028 units/L, total bilirubin
B

Figure 2. A. An MRI showed signal heterogeneity with multiple areas of hypointensity within the
body of the pancreas (yellow oval). B. An MRI showed lesions on the peripancreatic lymph node
(yellow circle).
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Figure 3. A. A CT of the abdomen and pelvis without contrast revealed mild inflammatory and
edematous changes of the pancreas (yellow circle). B. A CT of the abdomen and pelvis demonstrated dilatation of the gallbladder and common bile duct (yellow arrow), with an area of focal
narrowing within the distal common bile duct (blue arrow).
of 12.6 mg/dl, and direct bilirubin of 11.5 mg/dl.
decided to undergo palliative chemotherapy
A repeat CT of the abdomen and pelvis without and was discharged home.
contrast (Figure 3) demonstrated mild inflammatory changes involving the pancreas, dilataDiscussion
tion of the common bile duct and intrahepatic
Metastatic tumors to the pancreas are exbiliary tree, distended gallbladder, likely due to
tremely uncommon and only account for 2%
the obstructing neoplasm of the pancreas, and
of pancreatic malignancies.1 Tumors such as
numerous soft tissue masses in the retroperirenal cell carcinoma, breast, melanoma, colon,
toneum. Endoscopic retrograde cholangiopanand lung are all known to spread to the pancreatography (ERCP) (Figure 4) was performed creas.2 SCLC is known to have an aggressive
with a successful sphincterotomy at the major
metastatic pattern due to its lymphatic and
ampulla and a placement of 10 mm x 60 mm
hematogenous spread. More often, SCLC memetal stent in the common bile duct. The
tastasizes to the contralateral lung, brain, liver,
patient also received IV fluid and pain medicaadrenal glands, and bone.3 In rare occasions,
tions. His abdominal pain and jaundice resolved. SCLC can metastasize to the pancreas and is
AST, ALT, and ALP trended down. Given the
consistently associated with other intra-abrapid metastatic SCLC progression, the patient
A

B

Figure 4. A. An ERCP showed dilatation of the intrahepatic biliary tree (yellow oval), with focal
narrowing within the common bile duct (blue arrow). B. An ERCP showed successful placement
of stent within common bile duct (yellow oval).
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dominal metastatic sites such as the liver and
adrenal glands.4 SCLC metastasizing solely to
the pancreas is unique and can lead to complications such as recurrent acute pancreatitis
and ductal obstruction. On initial presentation,
our patient was found to have an acute pancreatitis episode with no evidence of pancreatic
neoplasm on a CT of the abdomen and pelvis.
The patient’s symptoms resolved with IV fluid
and pain medications and he was discharged
home. On the second admission, the patient’s
recurrent acute pancreatitis warranted further
evaluation given the recent history of being
diagnosed with SCLC and no other known
etiologies for his recurrent acute pancreatitis.
An MRI of the abdomen and pelvis demonstrated multiple pancreatic lesions. The endoscopic ultrasound with free needle aspiration
demonstrated that SCLC metastasized to the
pancreas. A PET scan performed during outpatient treatment was negative for any other
intra-abdominal tumors at that time, which
provided strong evidence that the patient had
a SCLC that had metastasized initially only to
the pancreas.
The initial approach to treatment of MIAP is
mainly conservative, consisting of IV fluid, pain
medications, and bowel rest. If the pancreatic lesion compresses the pancreatic duct, an
ERCP with a pancreatic duct stenting has a role
in improving clinical symptoms.5 In the patient’s
third presentation to the emergency room, he
was found to have new onset jaundice with elevated T-bilirubin, indicating a blockage to the
common bile duct. ERCP was able to detect a
stricture in the common bile duct, which was
likely a malignant stricture secondary to the
pancreatic metastatic neoplasm. After placement of the stent in the common bile duct, the
patient’s symptoms improved and the jaundice
resolved. Unfortunately, SCLC carries a poor
prognosis. In addition, the presence of metastatic SCLC to the pancreas indicates a very
poor prognosis and often an advanced SCLC
stage. Patients with advanced SCLC on chemotherapy that develop MIAP have a survival
time that varies from 4 to 6 months.6,7

Conclusion

Acute pancreatitis can occur due to multiple
different etiologies. Patients with a history
of lung malignancy presenting to the hospital
with acute pancreatitis should be further eval4

uated for the possibility of a metastatic cause
of pancreatitis. If a metastatic lesion is found
in the pancreas, treatment is typically directed
at symptomatic control but should be tailored
to each patient’s situation. Common managements include stent placement in the pancreatic duct and/or the common bile duct to relieve
the obstruction as well palliative chemotherapy
for patients with a rapidly progressing metastatic pancreatic lesion. While these approaches to management have shown benefits, patients with metastatic pancreatic lesions from
SCLC have very guarded prognoses.
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